Anal cancer is a rare type of cancer that begins in the anus, which is the tip of the rectum. Human papillomavirus (HPV), a sexually transmitted infection, is commonly associated with this type of cancer. It is found in the vast majority of cases of anal cancer. Some symptoms may include bleeding from the anal area, a lump or swelling near the anus, or a change in bowel habits, among others.
Factors such as the increasing prevalence of sexually transmitted diseases and anal cancer are expected to drive market growth. Furthermore, increased oncology research and development spending is expected to drive market growth. The high cost of anal cancer treatment and low awareness of this cancer are major market restraints. The anal cancer market is divided into three categories: type, treatment, and end-user.
Because of its well-developed healthcare sector, large patient population, and rising healthcare expenditures, the Americas leads the global anal cancer market. Furthermore, the presence of global companies such as Advaxis, Inc. in the region fuels market growth over the forecast period. In the presence of similar factors facilitating market growth within the region, the Americas are followed by Europe. Due to a large patient population and a continuously growing healthcare sector in developing economies such as India and China, Asia Pacific is the fastest-growing region. Furthermore, the market is being fueled by the growing geriatric population. The Middle East and Africa, on the other hand, have the smallest market share due to strict government policies and a lack of a developed healthcare sector, particularly in Africa.
Read more@ https://bit.ly/3cNAMAM